WHO ICTRP trial
A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants…
JPRN-jRCT2080225271 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2080225271 |
|---|---|
| Public title | A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa |
| Scientific title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa |
| Primary sponsor | UCB Japan Co., Ltd |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Japan;North America |
| Conditions | Hidradenitis Suppurativa |
| Interventions | investigational material(s) Generic name etc : UCB4940 INN of investigational material : bimekizumab Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigational material : 320mg… |
| Registration date | Sep 7, 2020 |
| Target size | 15 |
| Secondary IDs | NCT04242498;JapicCTI-205367 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: